Eli Lilly and Company (LLY)
Official siteHEALTHCARE • DRUG MANUFACTURERS - GENERAL • NYSE
Market Cap: $1.29T
Last updated: Nov 17, 2026 at 11:06 AM ET
Eli Lilly and Company (LLY) Earnings: Report Dates and Results
Eli Lilly and Company (LLY) is expected to report earnings on Feb 2, 2027. In the quarter ended Sep 30, 2026, Eli Lilly and Company reported EPS of $7.48, above the $5.38 estimate. It beat the EPS estimate in 7 of the last 8 quarters.
Earnings
Performance (10Y)
Upcoming Estimates
Next Report
LLY has an expected report date of Feb 2, 2027. Analysts' consensus for the quarter ending Dec 31, 2026 is 49.6% above the $7.54 reported for the quarter ended Dec 31, 2025.
LLY Earnings Call
The latest LLY earnings call transcript on file is labeled 2026Q3.
Read the 2026Q3 transcriptEarnings History
Of the 40 quarters below that had an estimate, LLY beat 28, missed 10 and matched 2. Revenue for the quarter ended Sep 30, 2026 was $24.40B, up 38.6% from $17.60B a year earlier.
| Quarter ended | EPS | Estimate | Range | Surprise | Result | YoY | Analysts | Revisions | Reported | Revenue |
|---|---|---|---|---|---|---|---|---|---|---|
| Sep 30, 2026 | $7.48 | $5.38 | $4.65 - $10.68 | +39.03% | Beat | +6.6% | 19 | 3 up, 7 down | Oct 29, 2026 | $24.40B |
| Jun 30, 2026 | $8.38 | $6.01 | $5.28 - $9.08 | +39.43% | Beat | +32.8% | 20 | 0 up, 16 down | Aug 5, 2026 | $22.97B |
| Mar 31, 2026 | $8.55 | $6.79 | $3.11 - $7.55 | +25.92% | Beat | +156.0% | 22 | 2 up, 13 down | Apr 30, 2026 | $19.80B |
| Dec 31, 2025 | $7.54 | $7.17 | $6.16 - $7.86 | +5.16% | Beat | +41.7% | 19 | 4 up, 9 down | Feb 4, 2026 | $19.29B |
| Sep 30, 2025 | $7.02 | $5.89 | $5.49 - $7.21 | +19.19% | Beat | +494.9% | 19 | 0 up, 12 down | Oct 30, 2025 | $17.60B |
| Jun 30, 2025 | $6.31 | $5.61 | $5.27 - $5.92 | +12.48% | Beat | +61.0% | 19 | 8 up, 6 down | Aug 7, 2025 | $15.56B |
| Mar 31, 2025 | $3.34 | $3.46 | $2.68 - $5.36 | -3.47% | Miss | +29.5% | 17 | 0 up, 9 down | May 1, 2025 | $12.73B |
| Dec 31, 2024 | $5.32 | $5.07 | $4.68 - $5.44 | +5.00% | Beat | +113.7% | 16 | 0 up, 12 down | Feb 6, 2025 | $13.53B |
| Sep 30, 2024 | $1.18 | $1.47 | $1.17 - $1.86 | -19.73% | Miss | +1080.0% | 15 | 0 up, 0 down | Oct 30, 2024 | $11.44B |
| Jun 30, 2024 | $3.92 | $2.77 | $2.22 - $3.22 | +41.52% | Beat | +85.8% | 9 | 2 up, 1 down | Aug 8, 2024 | $11.30B |
| Mar 31, 2024 | $2.58 | $2.49 | $2.22 - $2.78 | +3.61% | Beat | +59.3% | 16 | 2 up, 1 down | Apr 30, 2024 | $8.77B |
| Dec 31, 2023 | $2.49 | $2.37 | $2.04 - $2.56 | +5.06% | Beat | +19.1% | 13 | 0 up, 1 down | Feb 6, 2024 | $9.35B |
| Sep 30, 2023 | $0.10 | -$0.12 | -$0.90 - $0.35 | +183.33% | Beat | -94.9% | 10 | 1 up, 1 down | Nov 2, 2023 | $9.50B |
| Jun 30, 2023 | $2.11 | $1.99 | N/A | +6.03% | Beat | +68.8% | 17 | 6 up, 1 down | Aug 8, 2023 | $8.31B |
| Mar 31, 2023 | $1.62 | $1.73 | $1.32 - $1.92 | -6.36% | Miss | -38.2% | 17 | 4 up, 2 down | Apr 27, 2023 | $6.96B |
| Dec 31, 2022 | $2.09 | $1.83 | $1.60 - $2.10 | +14.21% | Beat | -16.1% | 16 | 1 up, 2 down | Feb 2, 2023 | $7.30B |
| Sep 30, 2022 | $1.98 | $1.94 | $1.80 - $2.19 | +2.06% | Beat | +2.1% | 7 | 1 up, 0 down | Nov 1, 2022 | $6.94B |
| Jun 30, 2022 | $1.25 | $1.70 | $1.48 - $1.84 | -26.47% | Miss | -33.2% | 8 | 3 up, 0 down | Aug 4, 2022 | $6.49B |
| Mar 31, 2022 | $2.62 | $2.29 | $1.83 - $2.50 | +14.41% | Beat | +40.1% | 7 | 4 up, 0 down | Apr 28, 2022 | $7.81B |
| Dec 31, 2021 | $2.49 | $2.51 | N/A | -0.80% | Miss | -9.5% | 8 | N/A | Feb 3, 2022 | $8.00B |
| Sep 30, 2021 | $1.94 | $1.96 | N/A | -1.02% | Miss | +26.0% | 6 | N/A | Oct 26, 2021 | $6.77B |
| Jun 30, 2021 | $1.87 | $1.89 | $1.77 - $2.04 | -1.06% | Miss | -1.1% | 12 | N/A | Aug 3, 2021 | $6.74B |
| Mar 31, 2021 | $1.87 | $2.10 | $1.98 - $2.35 | -10.95% | Miss | +6.9% | 11 | N/A | Apr 27, 2021 | $6.81B |
| Dec 31, 2020 | $2.75 | $2.39 | $2.12 - $2.45 | +15.06% | Beat | +59.0% | 14 | N/A | Jan 29, 2021 | $7.44B |
| Sep 30, 2020 | $1.54 | $1.71 | $1.50 - $1.84 | -9.94% | Miss | +4.1% | 12 | N/A | Oct 27, 2020 | $5.74B |
| Jun 30, 2020 | $1.89 | $1.60 | $1.11 - $1.67 | +18.13% | Beat | +26.0% | 12 | N/A | Jul 30, 2020 | $5.50B |
| Mar 31, 2020 | $1.75 | $1.48 | $1.17 - $1.68 | +18.24% | Beat | +31.6% | 11 | N/A | Apr 23, 2020 | $5.86B |
| Dec 31, 2019 | $1.73 | $1.52 | $1.44 - $1.59 | +13.82% | Beat | +30.1% | 10 | N/A | Jan 30, 2020 | $6.11B |
| Sep 30, 2019 | $1.48 | $1.41 | $1.25 - $1.45 | +4.96% | Beat | +6.5% | 10 | N/A | Oct 23, 2019 | $5.48B |
| Jun 30, 2019 | $1.50 | $1.45 | $1.42 - $1.47 | +3.45% | Beat | 0.0% | 10 | N/A | Jul 30, 2019 | $5.64B |
| Mar 31, 2019 | $1.33 | $1.33 | $1.06 - $1.41 | 0.00% | In line | -0.7% | 11 | N/A | Apr 30, 2019 | $5.09B |
| Dec 31, 2018 | $1.33 | $1.33 | $1.18 - $1.37 | 0.00% | In line | +16.7% | 12 | N/A | Feb 6, 2019 | $5.64B |
| Sep 30, 2018 | $1.39 | $1.35 | $1.19 - $1.42 | +2.96% | Beat | +32.4% | 12 | N/A | Nov 6, 2018 | $5.31B |
| Jun 30, 2018 | $1.50 | $1.30 | $1.24 - $1.33 | +15.38% | Beat | +35.1% | 12 | N/A | Jul 24, 2018 | $5.58B |
| Mar 31, 2018 | $1.34 | $1.13 | $1.08 - $1.18 | +18.58% | Beat | +36.7% | 16 | N/A | Apr 24, 2018 | $4.96B |
| Dec 31, 2017 | $1.14 | $1.07 | $1.00 - $1.11 | +6.54% | Beat | +20.0% | 17 | N/A | Jan 31, 2018 | $3.26B |
| Sep 30, 2017 | $1.05 | $1.03 | $0.98 - $1.07 | +1.94% | Beat | +19.3% | 18 | N/A | Oct 24, 2017 | $5.66B |
| Jun 30, 2017 | $1.11 | $1.05 | $1.00 - $1.11 | +5.71% | Beat | +29.1% | 17 | N/A | Jul 25, 2017 | $5.82B |
| Mar 31, 2017 | $0.98 | $0.96 | N/A | +2.08% | Beat | +18.1% | N/A | N/A | Apr 25, 2017 | $5.23B |
| Dec 31, 2016 | $0.95 | $0.98 | N/A | -3.06% | Miss | +21.8% | N/A | N/A | Jan 31, 2017 | $5.76B |
Annual EPS
EPS for the fiscal year ended Dec 31, 2025 was $24.21, up 86.2% from the year before. It was $3.52 for the year ended Dec 31, 2016, the oldest of the 10 fiscal years shown.
| Fiscal year ended | EPS | Change |
|---|---|---|
| Dec 31, 2025 | $24.21 | +86.2% |
| Dec 31, 2024 | $13.00 | +105.7% |
| Dec 31, 2023 | $6.32 | -20.4% |
| Dec 31, 2022 | $7.94 | -2.8% |
| Dec 31, 2021 | $8.17 | +3.0% |
| Dec 31, 2020 | $7.93 | +31.3% |
| Dec 31, 2019 | $6.04 | +8.6% |
| Dec 31, 2018 | $5.56 | +29.9% |
| Dec 31, 2017 | $4.28 | +21.6% |
| Dec 31, 2016 | $3.52 | N/A |
Earnings Calls
The 8 most recent earnings calls are listed below; the latest, 2026Q3 for the period ended Sep 30, 2026, runs about 9,500 words across 24 speakers.
| Call | Period ending | Words | Speakers | Transcript |
|---|---|---|---|---|
| 2026Q3 | Sep 30, 2026 | 9,475 | 24 | |
| 2026Q2 | Jun 30, 2026 | 8,894 | 22 | |
| 2026Q1 | Mar 31, 2026 | 8,160 | 20 | |
| 2025Q4 | Dec 31, 2025 | 9,775 | 23 | |
| 2025Q3 | Sep 30, 2025 | 8,710 | 23 | |
| 2025Q2 | Jun 30, 2025 | 8,171 | 22 | |
| 2025Q1 | Mar 31, 2025 | 9,526 | 27 | |
| 2024Q4 | Dec 31, 2024 | 8,478 | 24 |
2026Q3 Earnings Call
Opening remarks
Michael Czapar Senior Vice President of Investor Relations Good morning. Thank you for joining us for Eli Lilly and Company's Q3 2026 earnings call. I am Michael Czapar, Senior Vice President of Investor Relations. Joining me on today's call are David A. Ricks, Lilly's chair and CEO; Lucas E. Montarce, chief financial officer; Dr. Daniel Skovronsky, chief scientific and medical officer; Adrienne Brown, president of Lilly Immunology; Dr. Carole Ho, president of Lilly Neuroscience; Ilya Yuffa, president of Lilly USA and global customer capabilities; Jacob S. Van Naarden, president of Lilly Oncology and head of business development; Patrik Jonsson, president of Lilly International; and Kenneth Custer, president of Lilly Cardiometabolic Health. During this call, we anticipate making projections and forward-looking statements based on our current expectations. Our actual results could differ materially due to several factors, including those listed on slide 4. Additional information concerning factors that could cause actual results to differ is contained in our latest Form 10-Ks and subsequent filings with the SEC. Information we provide about our products and pipeline is for the benefit of the investment community. It is not intended to be promotional or otherwise influence prescribing decisions. Our commentary will focus on our non-GAAP financial measures. Now I will turn the call over to David.
David A. Ricks Chair and CEO Thank you, Mike. Q3 was another quarter of solid execution. We delivered strong financial results, raised our full-year financial guidance, advanced our pipeline, and expanded our manufacturing footprint. Revenue grew nearly $7 billion compared to Q3 2025, and our key product revenue increased by over $6 billion. Within key products, revenue from our oncology, immunology, and neuroscience portfolio doubled versus last year. We continued the global rollout of Foundayo, launching in the UK, Mexico, and Saudi Arabia for people with obesity, and in Mexico for people with type 2 diabetes. We achieved several key regulatory and pipeline milestones since our last call, including the U.S. approval of our new weekly insulin and new indications for Inluriyo, Jaypirca, and Mounjaro. As part of the Medicare GLP-1 Bridge Program, we expanded access to obesity medicines in the U.S. for approximately 20 million seniors. Since the July 1 launch, more than half a million people have filled a prescription for a Lilly medicine through this program. We have heard positive feedback from patients and physicians about the initial implementation. Within the GLP-1 Bridge Program, the Lilly portfolio is performing well. Among new Bridge patients, 7 out of 10 are starting on a Lilly obesity medicine. We are encouraged to see the strong uptake of the Bridge Program and believe it has the potential to both improve outcomes for seniors and save costs for Medicare.
Frequently Asked Questions About LLY
When is Eli Lilly and Company's next earnings date?
Eli Lilly and Company's next earnings report is expected for Feb 2, 2027.
Did LLY beat earnings estimates last quarter?
Yes. Eli Lilly and Company reported EPS of $7.48 for the quarter ended Sep 30, 2026, above the $5.38 estimate, a 39.03% surprise.
What EPS do analysts expect from LLY next quarter?
The consensus EPS estimate for Eli Lilly and Company for the quarter ending Dec 31, 2026 is $11.28 from 21 analysts, with estimates from $10.15 to $13.04.
How often does LLY beat earnings estimates?
Eli Lilly and Company beat the EPS estimate in 7 of the last 8 quarters, with an average surprise of +17.84%.
LLY pages: Overview, Dividends, Earnings, Forecast, Financials, Valuation, Competitors, Government Contracts